** Shares of Abbott Laboratories ABT.N fall 2.85% to $126.19
** A judge in the Whitfield infant formula case granted a retrial to the plaintiffs following the October 31, 2024 verdict that handed a unanimous win in favor of Abbott and Reckitt's RKT.L unit Mead Johnson
** The ruling found the companies were not liable for failing to warn of the risks around necrotizing enterocolitis $(NEC.AU)$ in their infant formula products
** Today's ruling marks a setback following what seemed like a step in the right direction - J.P.Morgan
** ABT shares up ~8% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。